Patients with metastatic non-small cell lung cancer who harbor HER2-mutations may develop brain metastases more frequently during treatment.
The FDA approved atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
Takeda announced that their ongoing phase III ALTA-1L trial of brigatinib reduced the risk of disease progression or death in adults with advanced ALK-positive non-small cell lung cancer.
The radiation oncologist from Memorial Sloan Kettering Cancer Center, discusses several ongoing trials combining immunotherapy and radiation at the 14th Annual New York Lung Cancers Symposium®.
The MSK expert discusses exciting advancements in the field of immunotherapy for treating lung cancer at the Annual New York Lung Cancers Symposium®.
Biomarker testing allows doctors to go beyond what’s under the microscope, helping to determine the best patient therapy.
Four cancer centers are joining forces on a new clinical trial designed to test medically tailored meals for patients with lung cancer to combat malnutrition.
Beth Eaby-Sandy, a nurse practitioner, discussed AEs associated with immunotherapy treatment in patients with lung cancer.
In our lung cancer quiz, you'll get a chance to test your knowledge of the management of sarcopenia in patients with lung cancer.
Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non–small cell lung cancer with PD-L1 expression ≥50%.